Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model.

  title={Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model.},
  author={E. Schmidt and P. Pattengale and L. Weir and P. Leder},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  volume={85 16},
  • E. Schmidt, P. Pattengale, +1 author P. Leder
  • Published 1988
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
Transgenic mice carrying a fusion gene in which the mouse immunoglobulin enhancer has been inserted into an otherwise normal human c-myc gene develop a narrow spectrum of pre-B-cell lymphomas. Tumor occurrence is correlated with expression of the transgene in organs in which large numbers of pre-B cells predominate. These tumors, which arise stochastically, are virtually all lymphoblastic lymphomas of the pre-B-cell type. Evidently the isolated enhancer targets oncogene expression and… Expand
A bcr-v-abl oncogene induces lymphomas in transgenic mice
In chronic myeloid leukemia and some cases of acute lymphoblastic leukemia, a 9;22 chromosome translocation has fused most of the c-abl oncogene to a gene designated bcr. To explore in vivo theExpand
Tumorigenesis in transgenic mice expressing the c-myc oncogene with various lymphoid enhancer elements.
The effects of NF-μNR deletion mutations on expression of c-myc transgenic constructs assessed at the level of transgene expression and tumor phenotypes were examined to observe tumors arising at earlier stages and originating from a wider spectrum of lymphoid development than was observed in previous studies. Expand
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis
A new, non-transgenic mouse model of B-lymphoma is established based on isolation of primary bone marrow cells, admixing them with packaging cells producing a Myc-encoding retrovirus (LMycSN), and subcutaneous injection into a host with which BM cells are syngeneic, suggesting that inactivation of p53 and overexpression of Myc is all that is necessary for the development of full-fledged B-LYmphomas. Expand
B-less: a strain of profoundly B cell-deficient mice expressing a human lambda transgene
Analysis of several transgenic mouse strains that bear the human lambda light chain gene shows it to be profoundly deficient in both immature (pre-B) and mature B cells, as well as in circulating immunoglobulin, and it is interesting that the deficiency phenotype is fully expressed in the FVB/N genetic background, but is suppressed in F1 hybrids formed between the FVP/N and C57BL/6 inbred strains. Expand
Strain dependency of B and T lymphoma development in immunoglobulin heavy chain enhancer (E mu)-myc transgenic mice
B6 and C3H/HeJ mice might provide the environment that supports the development or growth of B and T lymphomas, respectively, and that such an environment could be modified by irradiation of the mice. Expand
A transgenic model to study the role of oncogenes and tumour suppression genes in T cell lymphoma.
Tumourigenesis was not accelerated in animals heterozygous for the p53 null mutation suggesting that loss of both wild type p53 alleles was required for efficient synergy with the CD2-myc transgene, and the relatively weak synergy between these lesions compared to that observed with p53 loss and deregulated c- myc may be suggestive of a functional overlap between MoMuLV and p53 Loss. Expand
H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
  • J. Roland, D. Morello
  • Biology, Medicine
  • Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research
  • 1993
Several strains of transgenic mice were derived in which human c-myc genomic sequences were coupled to various regulatory sequences, H-2, E mu, and c- myc, and the quantity of transgene mRNA differed markedly among the transgenic strains, thus providing a situation in which the level of c-Myc expression could be correlated with tumor development. Expand
Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector
A new transgenic vector that should facilitate transgenic approaches to non-lymphoid leukemias is discussed, which bears elements from the promoter region of the vav gene, which has proven capable of driving transgene expression throughout the hematopoietic compartment, including progenitor cells and their precursors. Expand
B-less : a Strain of Profoundly B Cell-deficient Mice Expressing a Human ~ , Transgene By
We have created several transgenic mouse strains that bear the human 3 ̀light chain gene driven by its own promoter and a mouse immunoglobulin heavy chain enhancer. The transgene is expressed in manyExpand
A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice
Transgenic mice carrying an immunoglobulin enhancer-driven c-myc oncogene develop rapid-onset pre-B cell lymphomas. The incidence of these malignancies is greatly reduced when an additional transgeneExpand